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Effects of alirocumab on cardiovascular and metabolic 
outcomes after acute coronary syndrome in patients with or 
without diabetes: a prespecified analysis of the ODYSSEY 
OUTCOMES randomised controlled trial
Kausik K Ray*, Helen M Colhoun*, Michael Szarek*, Marie Baccara-Dinet, Deepak L Bhatt, Vera A Bittner, Andrzej J Budaj, Rafael Diaz, 
Shaun G Goodman, Corinne Hanotin, Robert A Harrington, J Wouter Jukema, Virginie Loizeau, Renato D Lopes, Angèle Moryusef, Jan Murin, 
Robert Pordy, Arsen D Ristic, Matthew T Roe, José Tuñón, Harvey D White, Andreas M Zeiher, Gregory G Schwartz*, Philippe Gabriel Steg*, for the 
ODYSSEY OUTCOMES Committees and Investigators†
Summary
Background After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A 
reduction in mean LDL cholesterol to 1·4–1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in 
patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL 
cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome 
is unknown. We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the 
PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also 
assessing its effects on glycaemic measures including risk of new-onset diabetes.
Methods ODYSSEY OUTCOMES was a randomised, double-blind, placebo-controlled trial, done at 1315 sites in 
57 countries, that compared alirocumab with placebo in patients who had been admitted to hospital with an acute 
coronary syndrome (myocardial infarction or unstable angina) 1−12 months before randomisation and who had 
raised concentrations of atherogenic lipoproteins despite use of high-intensity statins. Patients were randomly 
assigned (1:1) to receive alirocumab or placebo every 2 weeks; randomisation was stratified by country and was done 
centrally with an interactive voice-response or web-response system. Alirocumab was titrated to target LDL cholesterol 
concentrations of 0·65–1·30 mmol/L. In this prespecified analysis, we investigated the effect of alirocumab on 
cardiovascular events by glycaemic status at baseline (diabetes, prediabetes, or normoglycaemia)—defined on the 
basis of patient history, review of medical records, or baseline HbA1c or fasting serum glucose—and risk of new-onset 
diabetes among those without diabetes at baseline. The primary endpoint was a composite of death from coronary 
heart disease, non-fatal myocardial infarction, fatal or non-fatal ischaemic stroke, or unstable angina requiring 
hospital admission. ODYSSEY OUTCOMES is registered with ClinicalTrials.gov, number NCT01663402.
Findings At study baseline, 5444 patients (28·8%) had diabetes, 8246 (43·6%) had prediabetes, and 5234 (27·7%) had 
normoglycaemia. There were no significant differences across glycaemic categories in median LDL cholesterol at 
baseline (2·20–2·28 mmol/L), after 4 months’ treatment with alirocumab (0·80 mmol/L), or after 4 months’ treatment 
with placebo (2·25–2·28 mmol/L). In the placebo group, the incidence of the primary endpoint over a median of 
2·8 years was greater in patients with diabetes (16·4%) than in those with prediabetes (9·2%) or normoglycaemia 
(8·5%); hazard ratio (HR) for diabetes versus normoglycaemia 2·09 (95% CI 1·78–2·46, p<0·0001) and for diabetes 
versus prediabetes 1·90 (1·65–2·17, p<0·0001). Alirocumab resulted in similar relative reductions in the incidence of 
the primary endpoint in each glycaemic category, but a greater absolute reduction in the incidence of the primary 
endpoint in patients with diabetes (2·3%, 95% CI 0·4 to 4·2) than in those with prediabetes (1·2%, 0·0 to 2·4) or 
normoglycaemia (1·2%, –0·3 to 2·7; absolute risk reduction pinteraction=0·0019). Among patients without diabetes at 
baseline, 676 (10·1%) developed diabetes in the placebo group, compared with 648 (9·6%) in the alirocumab group; 
alirocumab did not increase the risk of new-onset diabetes (HR 1·00, 95% CI 0·89–1·11). HRs were 0·97 (95% CI 
0·87–1·09) for patients with prediabetes and 1·30 (95% CI 0·93–1·81) for those with normoglycaemia (pinteraction=0·11).
Interpretation After a recent acute coronary syndrome, alirocumab treatment targeting an LDL cholesterol 
concentration of 0·65–1·30 mmol/L produced about twice the absolute reduction in cardiovascular events among 
patients with diabetes as in those without diabetes. Alirocumab treatment did not increase the risk of new-onset 
diabetes.
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Introduction
Major guidelines for the prevention of cardiovascular 
disease agree that people with diabetes and established 
cardiovascular disease are in the highest risk category for 
future atherosclerotic cardiovascular disease, warranting 
intensive lipid lowering. However, guidelines vary with 
respect to the initiation threshold for intensified 
therapeutic approaches and potential treatment targets, 
emphasising the need for more evidence of absolute and 
relative treatment effects from intensive lipid lowering. 
Furthermore, in acute coronary syndromes, patients with 
diabetes have some of the highest reported rates of 
recurrent cardiovascular events,1,2 with the 2017 American 
College of Endocrinology guidelines referring to these 
patients as an extreme-risk group in whom physicians 
should aim for LDL cholesterol concentrations below 
1·42 mmol/L (55 mg/dL).3 Whether such patients benefit 
from achieving even lower LDL cholesterol concentrations 
(ie, below current treatment goals) is unknown.4,5
Observations that statins increase the risk of new-onset 
diabetes6,7 raise theoretical concerns that proprotein 
convertase subtilisin/kexin type 9 (PCSK9) inhibitors 
might also increase this risk, as has been suggested by 
findings from mendelian randomisation studies.8 A pooled 
analysis9 of the phase 3 trials of the PCSK9 inhibitor 
alirocumab showed no adverse effect of treatment on 
HbA1c or excess risk of new-onset diabetes; although 
reassuring, the number of years of exposure from this 
analysis is fairly small. Although there was no increased 
risk of new-onset diabetes with the PCSK9 inhibitor 
evolocumab compared with placebo over a median 
2·2 years (maximum 3·75 years) of follow-up in 
16 533 patients without diabetes at baseline, an increased 
risk of new-onset diabetes was seen among a subgroup of 
6189 patients with normoglycaemia at baseline (hazard 
ratio [HR] 1·60, 95% CI 1·13–2·28).10 A small but 
significant increase in fasting glucose without excess risk 
of new-onset diabetes was reported with bococizumab 
compared with placebo over a median exposure of about 
1 year.11 Further data in large populations over a longer 
observation period are needed to determine the 
glycometabolic safety of PCSK9 inhibition.
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Research in context
Evidence before this study
We searched PubMed for English-language articles published 
from database inception to June 1, 2019, using the search terms 
“cardiovascular events” or “outcomes” and “statin” or 
“ezetimibe” or “PCSK9” or “alirocumab” or “evolocumab”. 
We selected articles reporting cardiovascular outcomes trials or 
subanalyses thereof of cholesterol-lowering drugs. In patients 
with acute coronary syndromes, lowering LDL cholesterol to 
below 1·81 mmol/L (70 mg/dL) with statins, or further to around 
1·42 mmol/L (55 mg/dL) with statins plus ezetimibe, reduces 
cardiovascular disease events. Little evidence exists for lowering 
LDL cholesterol to 0·65–1·30 mmol/L (25–50 mg/dL) after an 
acute coronary syndrome event. The ODYSSEY OUTCOMES trial 
showed that the proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitor alirocumab, adjusted to target an LDL 
cholesterol concentration between 0·65 and 1·30 mmol/L, 
significantly reduced the risk of cardiovascular events after an 
acute coronary syndrome event. However, concerns have been 
raised about intensive lowering of LDL cholesterol because of 
evidence that statin therapy can increase the risk of diabetes in 
a dose-dependent manner. An analysis of a large cardiovascular 
outcomes trial (FOURIER) of the PCSK9 inhibitor evolocumab 
showed a consistent reduction in the relative risk of 
cardiovascular events in patients with or without diabetes at 
baseline and no increase in the risk of new-onset diabetes. 
However, the median and maximum durations of follow-up 
were fairly short and an excess risk of new-onset diabetes among 
patients with normoglycaemia at baseline was not excluded.
Added value of this study
In this prespecified analysis of the ODYSSEY OUTCOMES trial, 
in which we assessed the efficacy of alirocumab by glycaemic 
status, over a median follow-up of 2·8 years, the relative risk 
reduction for cardiovascular events achieved with alirocumab 
was similar among patients with normoglycaemia, 
prediabetes, or diabetes at baseline. However, the event rate 
in patients with diabetes at baseline was two-times higher 
than that in patients without, such that the absolute risk 
reduction with alirocumab for patients with diabetes was 
double that achieved in patients without diabetes. 
Reassuringly, despite achieving a median LDL cholesterol 
concentration of 0·80 mmol/L with alirocumab, assigned 
treatment had no effect on plasma glucose concentrations, 
HbA1c, or incident diabetes among 13 480 patients without 
diabetes at baseline, including 5955 patients followed up for 
3−5 years.
Implications of all the available evidence
Among patients with atherosclerotic cardiovascular disease, 
the presence of diabetes identifies a group with significantly 
higher risk of further cardiovascular events. In the setting of 
either stable cardiovascular disease or acute coronary 
syndrome, individuals with diabetes derive greater absolute 
benefit from the addition of a PCSK9 inhibitor to statin 
therapy to achieve LDL cholesterol concentrations well below 
current guideline recommendations. Consideration should be 
given to recommending LDL cholesterol goals in the 
0·65–1·30 mmol/L range for these high-risk individuals in 
future guidelines. Based on existing trial data, among the 
overall population without diabetes, PCSK9 inhibitors do not 
seem to increase the risk of new-onset diabetes.
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ODYSSEY OUTCOMES was a cardiovascular outcomes 
trial that compared treatment with alirocumab or 
placebo, beginning 1–12 months after an acute coronary 
syndrome event. Here, we report the efficacy of 
alirocumab on cardiovascular events by baseline 
glycaemic status and the effects of treatment on measures 
of glycaemia and new-onset diabetes.
Methods
Study design and participants
ODYSSEY OUTCOMES was a randomised, double-blind, 
placebo-controlled trial, done at 1315 sites in 57 countries, 
that compared alirocumab with placebo in patients who 
had been admitted to hospital with an acute coronary 
syndrome (myocardial infarction or unstable angina) 
1−12 months before randomisation. The trial design has 
been described previously.12 Randomisation outside of 
China was done between Nov 2, 2012, and Nov 11, 2015. 
In China, 614 patients were randomly assigned between 
May 5, 2016, and Feb 9, 2017. Patients had an LDL 
cholesterol concentration of at least 1·81 mmol/L 
(70 mg/dL), a non-HDL cholesterol concentration of at 
least 2·59 mmol/L (100 mg/dL), or an apolipoprotein B 
concentration of at least 0·8 g/L, measured after a 
minimum 2 weeks of stable treatment with atorvastatin 
40–80 mg daily, rosuvastatin 20–40 mg daily, or the 
maximum tolerated dose of one of these statins (including 
no statin in case of documented intolerance).
Ethics committee approval was obtained at all 
participating institutions. All participants provided 
informed consent.
Randomisation and masking
Patients were randomly assigned (1:1) to treatment with 
alirocumab 75 mg subcutaneously every 2 weeks or 
matching placebo, stratified by country. Randomisation 
was done centrally with an interactive voice-response or 
web-response system (appendix).
The treat-to-target design aimed to achieve an LDL 
cholesterol concentration of 0·65–1·30 mmol/L 
(25–50 mg/dL) among patients treated with alirocumab. 
Alirocumab 75 mg could be uptitrated to 150 mg if the 
LDL cholesterol concentration was 1·30 mmol/L or 
higher. If the LDL cholesterol concentration was less 
than 0·39 mmol/L (15 mg/dL) on two consecutive 
measurements on the 75 mg dose of alirocumab, placebo 
was substituted for the remainder of the trial. In patients 
who were given the 150 mg dose, the dose was 
downtitrated to 75 mg if the LDL cholesterol was less 
than 0·39 mmol/L on two consecutive measurements. 
The trial had a double-blind design, with patients and 
investigators masked to treatment assignment, including 
titration and substitution, and to lipid concentrations.
Procedures
Patients were classified into three prespecified baseline 
glycaemic categories: diabetes, prediabetes, and 
normoglycaemia. Diabetes was defined by one or more of 
the following criteria: type 1 or type 2 diabetes reported in 
the medical history or as an adverse event before first 
injection of study medication; HbA1c greater than 
6·5% (48 mmol/mol) at randomisation (or at the 
preceding screening visit if randomisation data were 
unavailable); fasting serum glucose concentration of 
7·0 mmol/L (126 mg/dL) or higher at both screening and 
randomisation visits; or use of diabetes medication before 
randomisation, with a diabetes diagnosis confirmed by an 
external diabetes expert committee that was masked to 
group assignment. Prediabetes was defined by one or 
more of the following criteria: impaired glucose control 
reported in the medical history or as an adverse event 
before first injection of study medication; HbA1c from 
5·7% (39 mmol/mol) to less than 6·5% (48 mmol/mol) at 
randomisation (or at the screening visit if randomisation 
data were unavailable); or fasting serum glucose 
concentration of at least 5·6 mmol/L at both screening 
and randomisation visits, but with no more than one 
value of 7·0 mmol/L or higher. Patients who did not meet 
the criteria for either diabetes or prediabetes were 
classified as normoglycaemic.
Outcomes
In this prespecified analysis, we examined the 
cardiovascular efficacy and safety of alirocumab by baseline 
diabetes status. As in the overall study, the primary 
endpoint for this analysis was the composite of death from 
coronary heart disease, non-fatal myocardial infarction, 
fatal or non-fatal ischaemic stroke, or unstable angina 
requiring hospital admission, analysed in the intention-to-
treat population (defined as all randomly assigned patients 
analysed according to allocated treatment group). All 
components of the primary composite endpoint were 
adjudicated with group assignment masked. In order to 
contextualise the effect of alirocumab on the primary 
endpoint (prespecified analysis) by diabetes status, we 
compared the association between presence of diabetes or 
absence of diabetes at study entry on the risk of the 
composite primary endpoint and its components (post-hoc 
analysis) in the placebo group. The effect of alirocumab on 
individual components of the composite primary endpoint 
was not analysed due to insufficient power.
The overall safety of alirocumab in ODYSSEY 
OUTCOMES has been reported previously.13 Prespecified 
secondary outcomes reported here are measures of 
glycometabolic safety, including the effects of alirocumab 
on HbA1c and fasting serum glucose concentration, 
analysed in the intention-to-treat population. New-onset 
diabetes was analysed in the safety population, consisting 
of randomly assigned patients who received at least one 
dose of study treatment, analysed according to the 
treatment actually received. The incidence of new-onset 
diabetes among participants with prediabetes or 
normoglycaemia was prespecified; we also report 
post-hoc HRs for new-onset diabetes in these two 
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subgroups. Principal analyses were done with Cox 
regression. Because alirocumab reduced the risk of dying 
from all causes, we also did competing-risk analyses to 
take survival benefit among alirocumab-treated patients 
into account with respect to new-onset diabetes. 
Individuals with normoglycaemia or prediabetes at 
baseline were considered to have new-onset diabetes 
during the trial if one or more of the following criteria 
were met: at least one HbA1c value of 6·5% or higher; 
two fasting serum glucose values of at least 7·0 mmol/L; 
an investigator-reported diabetes-related adverse event; 
or receipt of diabetes medication for a diagnosis of 
diabetes that was confirmed by an external expert 
committee who were masked to treatment assignment 
and post-randomisation lipid concentrations and who 
reviewed the medical history and other documentation 
(appendix).
We also report results of prespecified analyses of the 
effect of alirocumab on a range of lipid parameters (LDL 
cholesterol, non-HDL cholesterol, HDL cholesterol, and 
triglycerides) by baseline glycaemic category.
Statistical analysis
Time to first occurrence and cumulative incidence of the 
primary endpoint were determined within each baseline 
glycaemic category. Formal power calculations were not 
done for this prespecified analysis, but statistical 
assumptions for the overall trial have been reported 
previously,12 including a primary endpoint incidence rate 
of 11·4% at 4 years in the placebo group, a median 
baseline LDL cholesterol of 2·33 mmol/L (90 mg/dL), a 
reduction in LDL cholesterol of 50% with alirocumab, 
and an overall 15% reduction in the HR, providing 
90% power at a significance level of 0·05 with 
1613 primary endpoint events in the overall trial 
population. For each glycaemic category, treatment HRs 
and 95% CIs were estimated by Cox proportional-hazards 
models, stratified by geographical region. We calculated 
p values via stratified log-rank tests, using an intention-
to-treat analysis. Heterogeneity of alirocumab treatment 
effects by glycaemic category was assessed by Cox 
regression models with interaction terms for relative risk 
reduction and Gail-Simon tests for absolute risk 
reduction.
Among patients without diabetes at randomisation, 
HbA1c and fasting serum glucose concentrations were 
analysed in repeated-measures mixed-effects models with 
random effects for slope and intercept and fixed effects 
for treatment, baseline value, and time. If treatment with 
a diabetes medication was started, subsequent values of 
HbA1c and glucose were excluded from the analyses.
The ODYSSEY OUTCOMES trial is registered with 
ClinicalTrials.gov, number NCT01663402.
Role of the funding source
PGS, GGS, and MS developed the ODYSSEY 
OUTCOMES trial protocol and statistical analysis plan in 
conjunction with the other members of the executive 
steering committee, which includes representatives of 
the funders (appendix). The funders selected the study 
sites and monitored and supervised data collection. 
Analyses in the present report were performed 
independently of the funders by the academic statistician 
(MS); the funders contributed to data interpretation and 
provided input on the report. PGS, GGS, and MS had full 
access to all the data in the study. The executive steering 
committee decided to publish the paper and takes 
responsibility for the completeness and accuracy of the 
data and the fidelity of the trial to the protocol.
Results
Between Nov 2, 2012 and Feb 9, 2017, we randomly 
assigned 18 924 patients at 1315 sites in 57 countries 
(appendix). At randomisation, 5444 (28·8%) patients had 
Normoglycaemia 
(n=5234)
Prediabetes 
(n=8246)
Diabetes 
(n=5444)
Age, years 56 (50–63) 59 (52–65) 59 (53–66)
Sex
Women 1078 (20·6%) 1948 (23·6%) 1736 (31·9%)
Men 4156 (79·4%) 6298 (76·4%) 3708 (68·1%)
BMI, kg/m2 27 (25–30) 28 (25–31) 29 (26–33)
Blood pressure, mm Hg
Systolic 125 (115–135) 126 (117–137) 130 (120–140)
Diastolic 78 (70–83) 79 (70–83) 79 (70–84)
Index acute coronary syndrome event
Non-ST-segment elevation 
myocardial infarction
2478 (47·4%) 3921 (47·6%) 2776 (51·1%)
ST-segment elevation 
myocardial infarction
1922 (36·8%) 2971 (36·1%) 1643 (30·3%)
Unstable angina 826 (15·8%) 1344 (16·3%) 1012 (18·6%)
Laboratory values at randomisation
LDL cholesterol, mmol/L 2·23 (1·92–2·69) 2·28 (1·92–2·69) 2·20 (1·84–2·69)
Non-HDL cholesterol, 
mmol/L
2·90 (2·51–3·47) 2·97 (2·59–3·52) 3·03 (2·61–3·62)
HDL cholesterol, mmol/L 1·14 (0·98–1·35) 1·11 (0·96–1·32) 1·06 (0·91–1·24)
Triglycerides, mmol/L 1·32 (0·98–1·85) 1·44 (1·05–2·00) 1·66 (1·20–2·32)
HbA1c, % 5·4 (5·3–5·5) 5·9 (5·7–6·0) 7·0 (6·5–8·2)
Fasting serum glucose, 
mmol/L
5·2 (4·9–5·5) 5·6 (5·2–6·0) 7·4 (6·2–9·4)
High-intensity statin 
treatment*
4624 (88·3%) 7403 (89·8%) 4784 (87·9%)
Ezetimibe 171 (3·3%) 234 (2·8%) 149 (2·7%)
Fibrates 49 (0·9%) 95 (1·2%) 174 (3·2%)
Duration of follow-up, years 2·9 (2·3–3·5) 2·8 (2·3–3·4) 2·7 (2·3–3·4)
Eligible for ≥3 years of 
follow-up†
2405 (45·9%) 3550 (43·1%) 2287 (42·0%)
Data are n (%) or median (IQR). LDL cholesterol was calculated via the Friedewald formula. To convert the values for 
cholesterol to mg/dL, divide by 0·0259. To convert the values for triglycerides to mg/dL, divide by 0·0113. To convert 
the values for glucose to mg/dL, divide by 0·0555. *Atorvastatin 80 mg or rosuvastatin 40 mg. †Subset of participants 
that either were or could have been followed up for 3 years or longer because they were randomly assigned on or 
before Nov 11, 2014 (≥3 years before the common study end date).
Table: Baseline characteristics
Articles
622 www.thelancet.com/diabetes-endocrinology   Vol 7   August 2019
diabetes (n=37 with type 1 diabetes), 8246 (43·6%) 
patients had prediabetes, and 5234 (27·7%) patients had 
normo glycaemia. Within each glycaemic category, 
baseline characteristics were similar in the alirocumab 
and placebo groups (table, appendix). Most patients had 
coronary revascularisation for their index acute coronary 
syndrome event and received evidence-based treatment 
with dual antiplatelet therapy, β-blockers, and inhibitors 
of the renin-angiotensin system (appendix).
Baseline values of BMI, non-HDL cholesterol, and 
triglycerides were highest among patients with diabetes 
and lowest among those in the normoglycaemia group, 
with the opposite relation seen for HDL cholesterol 
concentrations. LDL cholesterol concentration did not 
differ across the three groups. Use of high-intensity statin 
by protocol was high overall (88·8% at baseline), but use 
of ezetimibe was low (2·9%), as was fibrate use (mostly 
fenofibrate; 1·7%). Of the 5444 patients with diabetes at 
baseline, 47 (0·9% [or 0·2% of the overall study population 
of 18 924]) were receiving a glucagon-like peptide-1 (GLP-1) 
receptor agonist at baseline and 26 (0·5% [0·1% of the 
overall study population]) were receiving a sodium-glucose 
co-transporter-2 (SGLT2) inhibitor at baseline (appendix); 
no patients in the prediabetes or normoglycaemia groups 
were receiving these medications. During the study, the 
number of participants using GLP-1 receptor agonists 
increased to 173 (0·9% of the total study population) and 
the number using SGLT2 inhibitors increased to 290 
(1·5% of the total study population) (appendix).
Median follow-up duration was 2·8 years, with 
8242 patients eligible for 3−5 years of follow-up (ie, 
randomly assigned at least 3 years before the common 
study end date of Nov 11, 2017). In the placebo group, 
the rate of the primary endpoint was 6·5 per 
100 person-years for patients with diabetes at baseline, 
3·4 per 100 person-years for those with prediabetes, 
and 3·1 per 100 person-years for those with 
normoglycaemia. The HR for the primary endpoint 
among patients with diabetes at baseline versus those 
with normoglycaemia was 2·09 (95% CI 1·78–2·46, 
p<0·0001); for those with diabetes versus those with 
prediabetes, the HR was 1·90 (1·65–2·17, p<0·0001; 
figure 1). There was no significant difference between 
those with normoglycaemia and those with prediabetes 
(data not shown). The presence of diabetes at baseline 
was associated with a significantly increased risk of the 
Figure 2: Lipid concentrations at 4 months after randomisation, by baseline glycaemic status (intention-to-treat analysis)
Error bars are IQRs. Median within-patient percentage changes from baseline are shown below each data point.
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Median follow-up was 2·8 years (IQR 2·3–3·4). There were no significant differences between participants with normoglycaemia and those with prediabetes for any of 
the outcomes (data not shown).
Major adverse cardiovascular
 events
8·5%
9·2%
16·4%
Death from coronary
heart disease
1·6% 1·9%
3·8%
Non-fatal myocardial 
infarction
6·0% 6·3%
11·2%
Ischaemic stroke
1·0% 1·3%
2·7%
Unstable angina
0·6% 0·5% 0·9%
18
0
3
6
9
12
15
24
21
In
cid
en
ce
 (%
)
HR 2·09 (1·78–2·46,
p<0·0001)
HR 2·54 (1·77–3·46,
p<0·0001)
HR 1·98 (1·63–2·40,
p<0·0001)
HR 2·89 (1·84–4·56,
p<0·0001)
HR 1·56 (0·82–2·98,
p=0·17)
HR 1·75 (0·98–3·15,
p=0·06)
HR 2·10 (1·48–2·99,
p<0·0001)
HR 1·88 (1·59–2·21,
p<0·0001)
HR 2·14 (1·60–2·88,
p<0·0001)
HR 1·90 (1·65–2·17,
p<0·0001)
Normoglycaemia
Prediabetes
Diabetes
Articles
www.thelancet.com/diabetes-endocrinology   Vol 7   August 2019 623
composite primary endpoint and all of its components 
apart from unstable angina (assessed in the placebo 
group) compared with those with normoglycaemia and 
those with prediabetes at baseline (figure 1).
Changes from baseline to month 4 in LDL cholesterol 
were similar in each glycaemic category (figure 2). 
In patients treated with alirocumab, median LDL 
cholesterol concentrations at month 4 were 
0·80 mmol/L (IQR 0·52–1·22) in those with diabetes, 
0·80 mmol/L (0·54–1·27) in those with prediabetes, 
and 0·80 mmol/L (0·54–1·30) in those with normo-
glycaemia. In patients given placebo, these values 
were 2·25 mmol/L (1·84–2·77) for those with diabetes, 
2·25 mmol/L (1·86–2·77) for those with prediabetes, 
and 2·28 mmol/L (1·89–2·77) for those with normo-
glycaemia. Over the course of the trial, patients treated 
with alirocumab had lower LDL cholesterol concentrations, 
irrespective of baseline glycaemic category (figure 3). The 
effects of alirocumab on non-HDL cholesterol, 
triglycerides, and HDL cholesterol were also similar 
across the baseline glycaemic categories (figure 2).
In the alirocumab group, the relative reduction in risk 
of the primary endpoint was similar among patients 
with diabetes (HR 0·84, 95% CI 0·74–0·97), 
prediabetes (0·86, 0·74–1·00), and normoglycaemia 
(0·85, 0·70–1·03). However, the substantially higher 
absolute risk among patients with diabetes resulted in a 
greater absolute risk reduction with alirocumab treatment 
(2·3%, 95% CI 0·4 to 4·2) compared with patients with 
prediabetes (1·2%, 0·0 to 2·4) or normoglycaemia (1·2%, 
–0·3 to 2·7; pinteraction=0·0019 among the three glycaemic 
categories), resulting in a number needed to treat of 43 
for people with diabetes and 82 for those without (figure 4, 
appendix).
Of the patients without diabetes at baseline, 
5955 (44·2%) were eligible for 3−5 years of follow-up 
(table). In patients without diabetes at baseline, mean 
HbA1c after randomisation was slightly lower in the 
alirocumab group than in the placebo group 
(5·78% vs 5·80%, p=0·0008), with no difference in mean 
fasting glucose concentrations (5·67 vs 5·68 mmol/L, 
p=0·84; figure 5). These findings were similar among 
patients with either prediabetes (HbA1c: 5·92% with 
alirocumab vs 5·95% with placebo; fasting serum glucose 
5·85 vs 5·85 mmol/L) or normoglycaemia (HbA1c: 5·55% 
vs 5·56%; fasting serum glucose: 5·40 vs 5·40 mmol/L) at 
baseline (figure 5). The risk of developing new-onset 
diabetes in patients without diabetes at baseline did not 
differ between alirocumab and placebo: 648 patients 
(9·6%) in the alirocumab group developed diabetes after 
randomisation, compared with 676 patients (10·1%) in 
the placebo group (HR 1·00, 95% CI 0·89−1·11). As 
expected, developing diabetes during the trial was more 
common in patients with prediabetes at baseline 
(13·8% [570/4128] in the alirocumab group and 
15·3% [614/4017] in the placebo group) than in those who 
were normoglycaemic at baseline (3·0% [78/2635] and 
2·4% [62/2589]). There were 13 459 patients in the safety 
population who had normoglycaemia or prediabetes at 
baseline; 1324 of these patients had new-onset diabetes 
and there were 348 competing deaths (152 in the 
alirocumab group and 196 in the placebo group). In a 
competing-risks model, the treatment HR for new-onset 
diabetes for the patients with baseline normoglycaemia 
or prediabetes was 0·95 (95% CI 0·85−1·05). In a model 
Figure 3: LDL cholesterol concentrations over time (intention-to-treat analysis)
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including the interaction with normoglycaemia and 
prediabetes status, the subgroup HRs were 1·23 (95% CI 
0·88−1·71) for those with baseline normoglycaemia and 
0·92 (0·82−1·03) for those with baseline prediabetes 
(pinteraction=0·11).
Discussion
Abnormal glycometabolic status is common in patients 
after an acute coronary syndrome, with about a third 
having diabetes and a similar proportion having 
prediabetes.14 After an acute coronary syndrome, patients 
with diabetes are at particularly high risk of recurrent 
ischaemic cardiovascular events, and also derive the 
greatest absolute benefit from a given degree of lipid 
lowering with high-intensity statins15 or statins plus 
ezetimibe.2,16
The distribution of patients with glycometabolic 
abnormalities in our trial was similar to that in an earlier 
study of people with a previous acute coronary syndrome,14 
with about 70% of the cohort having diabetes or 
prediabetes. The presence of diabetes at baseline did not 
affect LDL cholesterol concentrations at baseline or during 
assigned treatment with alirocumab or placebo. In the 
placebo group of the present study, the annual event rate 
of the primary outcome among patients with diabetes at 
baseline was 6·5 per 100 person-years, compared with 
3·4 per 100 person-years among those with prediabetes 
and 3·1 per 100 person-years in those with 
normoglycaemia. Although age and BMI were higher in 
patients with baseline diabetes than in those with 
normoglycaemia, lipid profiles were only modestly worse 
in those with diabetes at baseline (table). In a study with 
Figure 4: Relative and absolute risk reduction with alirocumab, by baseline glycaemic status
Median follow-up was 2·8 years (IQR 2·3–3·4). MACE=major adverse cardiovascular events.
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an average follow-up duration of 2·8 years, it is unlikely 
that these differences alone would result in a doubling of 
the absolute risk of cardiovascular events. Thus, our 
observed event rate in the placebo group reinforces the 
hypothesis that the presence of diabetes per se carries a 
significant excess cardiovascular risk in patients with a 
recent acute coronary syndrome. The relative reduction in 
risk of ischaemic cardiovascular events with alirocumab 
compared with placebo was similar between those with 
and without diabetes. However, patients with diabetes, 
compared to those without diabetes, had a substantially 
higher absolute risk of recurrent cardiovascular events 
after acute coronary syndrome and about twice the 
absolute reduction in that risk with alirocumab 
(2·3% vs 1·2%). These benefits were achieved on a 
background of extensive use of evidence-based therapies, 
including high-intensity statins, revascularisation for the 
index acute coronary syndrome event, dual antiplatelet 
therapy, and blockade of the β-adrenergic and renin−
angiotensin systems, and with good control of blood 
glucose (mean baseline HbA1c of 7·0% in patients with 
diabetes at baseline).
Our findings build upon previous evidence supporting 
the use of intensive lipid-lowering therapy and ezetimibe 
in patients with diabetes and acute coronary syndrome, 
and are aligned with the recent updating of some clinical 
guidelines3,17,18 in which LDL cholesterol treatment goals 
have been successively lowered from less than 
2·59 mmol/L to less than 1·81 mmol/L,17,18 and even to 
less than 1·42 mmol/L,3 in these very high-risk patients. 
The American College of Cardiology and American 
Heart Association guidelines—although acknowledging 
that PCSK9 inhibitors are an option to lower LDL 
cholesterol to below 1·81 mmol/L in very high-risk 
patients—noted that PCSK9 inhibitors are likely to be 
less cost-effective than ezetimibe. These guidelines 
suggest that there is a need to easily identify very high-
risk groups who derive greater absolute benefits from 
these more expensive therapies. The findings of our 
study suggest that, among patients with a recent acute 
coronary syndrome, the presence of diabetes highlights 
a large subgroup (about a third) with substantially 
enhanced risk and who derive greater benefits from 
targeting even lower LDL cholesterol concentrations of 
0·65–1·30 mmol/L. The corresponding number needed 
to treat for a median of 2·8 years to avoid one primary 
endpoint event was 43 for patients with diabetes at 
baseline versus 82 for patients without diabetes 
at baseline. Accordingly, patients with diabetes and acute 
coronary syndrome are a group in whom the cost-
effectiveness of alirocumab treatment is more 
favourable.
An additional goal of our study was to examine the 
glycaemic safety of alirocumab treatment among patients 
without diabetes at baseline. Concerns about the effects of 
lipid-lowering therapies on glucose homeostasis have 
come from observations that statins increase the risk of 
new-onset diabetes by 9% versus placebo, and by an 
additional 12% when comparing high-intensity statins 
with moderate-intensity statins.7 Furthermore, mendelian 
randomisation studies8,19–21 of genetic polymorphisms that 
mimic the effects of statins, ezetimibe, or PCSK9 
inhibitors suggest that lifelong reductions in LDL 
cholesterol, irrespective of the mechanism, are associated 
with an increased risk of diabetes. These findings have 
raised theoretical concerns about the risk of new-onset 
diabetes with the use of PCSK9 inhibitors.
In the present analysis, no excess risk of new-onset 
diabetes with alirocumab was seen in patients with 
prediabetes or normoglycaemia at baseline. Findings 
from an analysis of the FOURIER cardiovascular 
outcomes trial10 with the PCSK9 inhibitor evolocumab 
suggested a possible increased risk of new-onset diabetes 
among patients with normoglycaemia at baseline, but 
not among those with prediabetes at baseline, albeit with 
a small number of events and wide CIs. This finding was 
not seen in the present analysis, with no adverse effect of 
alirocumab on HbA1c, fasting glucose, or new-onset 
diabetes in patients with either normoglycemia or 
prediabetes at baseline.
There are some notable differences between the 
methods used to assess glycaemic safety in the FOURIER 
trial10 and in the current analysis. Our trial had longer 
follow-up than FOURIER to assess safety and efficacy and 
a masked diabetes endpoint adjudication committee to 
determine cases of new-onset diabetes. In the present 
analysis, fasting glucose and HbA1c values collected after 
initiation of diabetes medication were censored because 
initiation of diabetes medications would lower any 
subsequent measurements of glucose concentration and 
HbA1c, and thus confound the assessment of any direct 
effect of randomised treat ment assignment on these 
measures. Because such censoring was not used in the 
FOURIER analysis, a potential effect of study treatment 
on glucose or HbA1c could have been masked.10 The 
present findings provide greater reassurance about the 
glycaemic safety of PCSK9 inhibitors as a class. However, 
new-onset diabetes with statins was only confirmed many 
years after regulatory approval through meta-analyses of 
multiple trials. Thus, although the present results are 
reassuring, the long-term effects (ie, beyond 5 years) of 
PCSK9 inhibitors on glycaemic status are still unknown.
Mendelian randomisation analyses8,20,21 have shown 
that genetically determined loss of function of PCSK9 is 
associated with an increased risk of incident diabetes, 
but clinical trials of PCSK9 inhibitors have shown no 
such effect.9 These findings, although divergent, might 
not necessarily be inconsistent. First, the timeframe of 
mendelian randomisation analyses is substantially 
longer than that of clinical trials, providing more 
opportunity to observe the effects of genetic variants in 
PCSK9 on incident diabetes. Second, in clinical trials 
that enrol patients with established atherosclerosis, 
about 70% already have a glycometabolic abnormality at 
Articles
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randomisation (prediabetes or diabetes). The effects of 
pharmacological PCSK9 inhibition on incident diabetes 
in such a population could be different than the 
longitudinal effects of genetic variants in PCSK9 in a 
healthy population with a low prevalence of glycaemic 
abnormality at baseline.
Mostly, the analyses of the FOURIER10 and ODYSSEY 
OUTCOMES trials have consistent findings with respect 
to diabetes. FOURIER used a fixed dose of evolocumab 
and the LDL cholesterol concen trations described are for 
patients who remained on treatment, had follow-up 
laboratory measurements, and had no change in 
background statin treatment. By contrast, the LDL 
cholesterol concentrations presented in our study are 
from the intention-to-treat analysis and ODYSSEY 
OUTCOMES used a treat-to-target design. Despite these 
differences, the results among participants with diabetes 
at baseline were similar. The relative risk reduction for 
the primary endpoint of five-point major adverse 
cardiovascular events in FOURIER among those with 
diabetes at baseline was 17%, similar to the 16% relative 
reduction in the risk of four-point major adverse 
cardiovascular events in ODYSSEY OUTCOMES. At 
3 years, the proportion of individuals with diabetes in the 
placebo group who had experienced a primary endpoint 
event was 17·1% in FOURIER, and was reduced in 
absolute terms by 2·7% with evolocumab. In ODYSSEY 
OUTCOMES, at the median follow-up of 2·8 years, the 
comparable figures for individuals with diabetes were a 
16·4% risk of a primary endpoint event among patients 
in the placebo group, which was reduced in absolute 
terms by 2·3% with alirocumab treatment.
Although patients with prediabetes have been reported 
to have worse cardiovascular outcomes than those with 
normoglycaemia,22,23 the observed rates were similar in the 
present analysis. This finding might reflect the fact that 
we used both contemporary HbA1c definitions and fasting 
glucose criteria to define glycaemic status, so that patients 
who might historically have been classified as having 
prediabetes would now be classified as having diabetes by 
the present definition. An alternative explanation for the 
similar event rates between those with prediabetes and 
normoglycaemia could be index event bias (ie, in a 
population defined by acute coronary syndrome, those 
with normoglycaemia are enriched with other competing 
risk factors, identifiable or not). In this regard, high use of 
aggressive lipid-lowering and other guideline-based 
secondary prevention therapies (appendix) might mean 
that the median follow-up of 2·8 years was not long 
enough to observe the previously well-established 
differences in risk between those with prediabetes and 
those with normoglycaemia in population-based cohort 
studies with longer follow-up durations. Our findings of a 
consistent relative benefit of alirocumab among patients 
with normoglycaemia, prediabetes, or diabetes in the 
post-acute coronary syndrome setting is consistent with, 
and extends, previous observations in stable cardiovascular 
disease, in which people with and without diabetes derive 
similar relative benefits from PCSK9 inhibition.10
A limitation of our study is that it was started before 
GLP-1 receptor agonists24 and SGLT2 inhibitors25 were 
shown to reduce major cardiovascular events and 
mortality in patients with stable cardiovascular disease 
and type 2 diabetes. At baseline, 0·2% (n=47) of the total 
study population were receiving a GLP-1 receptor agonist, 
which increased to 0·9% (n=173) during the study 
(appendix). For SGLT2 inhibitors, the corresponding 
numbers were 0·1% (n=26) at baseline, increasing to 
1·5% (n=290) during the study. It is uncertain whether 
greater use of these classes of drugs would affect the 
magnitude of the observed benefit of alirocumab 
treatment in patients with acute coronary syndrome and 
diabetes, although the evidence to date suggests that the 
benefits of newer diabetes treatments and lipid lowering 
are complementary.26 Moreover, GLP-1 receptor agonists 
and SGLT2 inhibitors have shown benefit in patients with 
chronic stable cardiovascular disease, but efficacy has not 
been shown in the post-acute coronary syndrome setting.27
In summary, in the post-acute coronary syndrome 
context, compared with patients without diabetes, those 
with diabetes had twice the excess risk of cardiovascular 
events when LDL cholesterol was greater than 1·8 mmol/L 
despite intensive statin treatment. The patients with 
diabetes also derived twice as much benefit when 
alirocumab was used to target an LDL cholesterol 
concentration between 0·65 mmol/L and 1·30 mmol/L. 
With a median follow-up of 2·8 years and with 
5955 (44·2%) patients without diabetes eligible for 
3−5 years of follow-up, alirocumab did not adversely affect 
measures of glycaemia or increase the risk of new-onset 
diabetes. These findings provide further evidence that 
future guidelines should recommend much lower LDL 
cholesterol targets for patients with vascular disease when 
diabetes is present.
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